In summary, our study uncovers that the upregulation of PDGFRA confers resistance to lenvatinib therapy in HCC cells via the PTEN/AKT/GSK-3β/β-catenin signaling cascade. This evidence concerns the gene PDGFRA and hepatocellular carcinoma.